- Report
- February 2025
- 144 Pages
Global
From €2726EUR$2,999USD£2,315GBP
- Report
- March 2025
- 147 Pages
Global
From €2726EUR$2,999USD£2,315GBP
- Report
- August 2024
- 137 Pages
Global
From €2726EUR$2,999USD£2,315GBP
- Report
- August 2024
- 140 Pages
Global
From €2726EUR$2,999USD£2,315GBP
- Report
- May 2024
- 136 Pages
Global
From €5907EUR$6,499USD£5,016GBP
- Report
- December 2024
- 200 Pages
Global
From €2272EUR$2,500USD£1,930GBP
- Report
- January 2025
- 180 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- April 2025
- 80 Pages
Global
From €1818EUR$2,000USD£1,544GBP
- Report
- April 2025
- 100 Pages
Global
From €1818EUR$2,000USD£1,544GBP
- Report
- April 2025
- 60 Pages
Global
From €1363EUR$1,500USD£1,158GBP
- Report
- April 2025
- 70 Pages
Global
From €1363EUR$1,500USD£1,158GBP
- Report
- April 2025
- 60 Pages
Global
From €1363EUR$1,500USD£1,158GBP
- Report
- April 2025
- 50 Pages
Global
From €1363EUR$1,500USD£1,158GBP
- Report
- April 2025
- 60 Pages
Global
From €1136EUR$1,250USD£965GBP
- Report
- April 2025
- 60 Pages
Global
From €1136EUR$1,250USD£965GBP
- Report
- April 2025
- 120 Pages
Global
From €1818EUR$2,000USD£1,544GBP
- Report
- April 2025
- 60 Pages
Global
From €1818EUR$2,000USD£1,544GBP
- Report
- December 2024
- 119 Pages
Global
From €3590EUR$3,950USD£3,049GBP
- Report
- July 2024
- 100 Pages
Global
From €3409EUR$3,750USD£2,894GBP
- Report
- January 2025
- 250 Pages
Global
From €4544EUR$4,999USD£3,858GBP

The Antimicrobial Resistance (AMR) market is a subset of the healthcare services industry that focuses on the development of treatments and strategies to combat the growing threat of drug-resistant bacteria. AMR is a major public health concern, as it can lead to increased morbidity and mortality, as well as higher healthcare costs. To address this issue, the market is focused on developing new antibiotics, diagnostics, and vaccines, as well as strategies to reduce the spread of drug-resistant bacteria. Additionally, the market is focused on improving the stewardship of existing antibiotics, as well as developing new strategies to reduce the emergence of drug-resistant bacteria.
Some companies in the AMR market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, Novartis, and AstraZeneca. Show Less Read more